Intercept Pharmaceuticals’ (ICPT) Buy Rating Reaffirmed at Wedbush
Wedbush restated their buy rating on shares of Intercept Pharmaceuticals (NASDAQ:ICPT) in a research note issued to investors on Monday morning, AnalystRatings.com reports. They currently have a $257.00 price objective on the biopharmaceutical company’s stock.
Several other brokerages have also recently issued reports on ICPT. Jefferies Financial Group set a $125.00 price target on Intercept Pharmaceuticals and gave the company a buy rating in a research report on Friday, October 18th. Robert W. Baird restated a buy rating and issued a $227.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Needham & Company LLC restated a buy rating and issued a $150.00 price target on shares of Intercept Pharmaceuticals in a research report on Tuesday, December 17th. Stifel Nicolaus boosted their price target on Intercept Pharmaceuticals from $86.00 to $102.00 in a research report on Monday, November 25th. Finally, Canaccord Genuity initiated coverage on Intercept Pharmaceuticals in a research report on Monday, December 2nd. They issued a buy rating on the stock. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $141.65.
ICPT opened at $94.69 on Monday. The business’s 50-day simple moving average is $106.09 and its 200-day simple moving average is $84.93. The company has a debt-to-equity ratio of 4.02, a quick ratio of 5.49 and a current ratio of 5.49. Intercept Pharmaceuticals has a one year low of $56.76 and a one year high of $131.87. The stock has a market capitalization of $3.17 billion, a P/E ratio of -8.71 and a beta of 1.74.
Several hedge funds have recently added to or reduced their stakes in the company. Amalgamated Bank increased its holdings in shares of Intercept Pharmaceuticals by 7.3% during the 4th quarter. Amalgamated Bank now owns 4,701 shares of the biopharmaceutical company’s stock worth $583,000 after buying an additional 319 shares during the last quarter. CIBC World Markets Inc. acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $223,000. Amia Capital LLP acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $951,000. Financial Advocates Investment Management acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $273,000. Finally, Renaissance Technologies LLC acquired a new stake in shares of Intercept Pharmaceuticals during the 4th quarter worth $11,425,000. Institutional investors and hedge funds own 79.14% of the company’s stock.
Intercept Pharmaceuticals Company Profile
Intercept Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases. It markets Ocaliva, an farnesoid X receptor agonist approved in the United States, the European Union, and other jurisdictions for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults.
Featured Article: How is diluted EPS different from basic EPS?
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.